Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now

DENTSPLY SIRONA (XRAY) is focusing on growth through its digital-implant workflow and R&D, with Q1 2025 showing a 46.9% increase in adjusted operating profit and margin expansion of 305 bps. The company is leveraging its Azento solution in the $20 billion tooth replacement market and scaling up in clear aligners. However, a 3.7% revenue decrease is expected in 2025 due to soft CAD/CAM demand in Europe, particularly Germany, and forex headwinds.

Analysis

DENTSPLY SIRONA (XRAY) presents a mixed operational and market outlook. The company is strategically pursuing growth through its new digital-implant workflow, notably the Azento solution, and a heightened focus on research and development, positioning itself within the expansive $20 billion global tooth-replacement market and scaling its clear aligner business. First-quarter 2025 results were encouraging, with better-than-expected performance, a 46.9% year-over-year increase in adjusted operating profit to $72 million, and a significant 305 basis point expansion in adjusted operating margin to 8.2%, partly driven by strength in its Wellspect Healthcare segment. R&D expenditure was $36 million in Q1 2025, reflecting an ongoing commitment to product innovation. However, XRAY faces considerable challenges: its shares have declined 13.6% year-to-date, starkly underperforming its industry and the S&P 500. This underperformance is attributed to persistent softness in demand for CAD/CAM products in Europe, particularly Germany, and adverse foreign exchange movements, which are expected to contribute to a projected 3.7% decrease in 2025 revenues to $3.65 billion. Despite these revenue headwinds, the Zacks Consensus Estimate for 2025 adjusted earnings per share is $1.90, indicating a noteworthy 13.8% year-over-year improvement, and the company anticipates earnings to improve 7.4% over the next five years.

Key Decisions for Investors

• Investors should closely monitor the evolving demand situation for CAD/CAM products in Europe, especially Germany, and the impact of foreign exchange fluctuations, as these are critical factors affecting XRAY's near-term revenue trajectory.
• Consider the disconnect between the stock's year-to-date underperformance (-13.6%) and the company's reported Q1 2025 adjusted operating margin expansion (305 bps) and projected 13.8% growth in 2025 adjusted EPS, evaluating if current headwinds are adequately priced in.
• Evaluate DENTSPLY SIRONA's ability to successfully leverage its increased R&D spending and new digital solutions like Azento to capture market share in the $20 billion tooth-replacement segment and offset the anticipated 2025 revenue decline through improved profitability and innovation-driven growth.